Active Ingredient(s):Viltolarsen FDA Approved: * August 12, 2020 Pharm Company: *NIPPON SHINYAKU Category:Genetic Disorders
Viltolarsen, sold under the brand name Viltepso, is a medication used for the treatment of Duchenne muscular dystrophy (DMD). Viltolarsen is a Morpholino antisense oligonucleotide.
The most common side effects include upper respiratory tract infection, injection site reaction, cough, and pyrexia (fever).
Viltolarsen was approved for medical us...
* May have multiple approval dates, manufacturers, or labelers.